创新药泽立美乳膏获特应性皮炎临床指南重点推荐

中金在线10-20

《特应性皮炎外用治疗与管理专家共识(2025版)》(以下简称《共识》)日前在《中华皮肤科杂志》正式刊发。该共识由北京大学人民医院皮肤科张建中教授担任通信作者，联合国内32位皮肤科、变态反应科及儿科学专家共同制定，首次对原研创新药物泽立美本维莫德乳膏作出规范化临床应用指导。《共识》指出，特应性皮炎(AD)在我国儿童群体中患病率达10%-15%，疾病负担居非致命性皮肤病首位。针对占比达三分之二的轻中度...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2576837149?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-20 16:48","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2576837149","market":"us","top_or_hot":-1,"title":"创新药泽立美乳膏获特应性皮炎临床指南重点推荐","media":"中金在线","content":"<div>\n<p>《特应性皮炎外用治疗与管理专家共识(2025版)》(以下简称《共识》)日前在《中华皮肤科杂志》正式刊发。该共识由北京大学人民医院皮肤科张建中教授担任通信作者，联合国内32位皮肤科、变态反应科及儿科学专家共同制定，首次对原研创新药物泽立美本维莫德乳膏作出规范化临床应用指导。《共识》指出，特应性皮炎(AD)在我国儿童群体中患病率达10%-15%，疾病负担居非致命性皮肤病首位。针对占比达三分之二的轻中度...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020165638a6c365a8&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>创新药泽立美乳膏获特应性皮炎临床指南重点推荐</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n创新药泽立美乳膏获特应性皮炎临床指南重点推荐\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-20 16:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020165638a6c365a8&s=b><strong>中金在线</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>《特应性皮炎外用治疗与管理专家共识(2025版)》(以下简称《共识》)日前在《中华皮肤科杂志》正式刊发。该共识由北京大学人民医院皮肤科张建中教授担任通信作者，联合国内32位皮肤科、变态反应科及儿科学专家共同制定，首次对原研创新药物泽立美本维莫德乳膏作出规范化临床应用指导。《共识》指出，特应性皮炎(AD)在我国儿童群体中患病率达10%-15%，疾病负担居非致命性皮肤病首位。针对占比达三分之二的轻中度...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020165638a6c365a8&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AD","symbol_name":"Array Digital Infrastructure Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020165638a6c365a8&s=b","article_id":"2576837149","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020165638a6c365a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2576837149","pubTimestamp":1760950084,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"在芳香烃受体调节剂中，上海泽德曼医药科技有限公司于2024年11月上市的泽立美本维莫德乳膏，在我国已获批用于治疗2 岁及以上儿童和成人轻中度AD。《共识》指出，泽立美本维莫德乳膏可通过抑制2型炎症细胞因子和修复皮肤屏障发挥治疗作用。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"AD":"Array Digital Infrastructure Inc.","BK4132":"无线电信业务"},"translate_title":"The innovative drug Zelimei cream is highly recommended by the clinical guidelines for atopic dermatitis","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AD":1},"content_text":"《特应性皮炎外用治疗与管理专家共识(2025版)》(以下简称《共识》)日前在《中华皮肤科杂志》正式刊发。该共识由北京大学人民医院皮肤科张建中教授担任通信作者，联合国内32位皮肤科、变态反应科及儿科学专家共同制定，首次对原研创新药物泽立美本维莫德乳膏作出规范化临床应用指导。《共识》指出，特应性皮炎(AD)在我国儿童群体中患病率达10%-15%，疾病负担居非致命性皮肤病首位。针对占比达三分之二的轻中度患者，专家团队基于中国人群研究数据，将芳香烃受体调节剂泽立美本维莫德乳膏列为重要治疗选择。此次发布的《共识》历经4轮专家论证，参考国内外65项研究证据，首次建立符合中国患者特征的规范化外用药诊疗体系。据循证医学证据显示，芳香烃受体(aryl hydrocarbons receptor，AhR)是介导环境因素与免疫系统细胞成分相互作用的一种细胞信号传导体。皮肤细胞表达 AhR受体，AhR通路参与维持皮肤稳态和皮肤炎症。在芳香烃受体调节剂中，上海泽德曼医药科技有限公司于2024年11月上市的泽立美本维莫德乳膏，在我国已获批用于治疗2 岁及以上儿童和成人轻中度AD。《共识》指出，泽立美本维莫德乳膏可通过抑制2型炎症细胞因子和修复皮肤屏障发挥治疗作用。泽立美本维莫德可抑制白细胞介素(IL)-4/IL-13诱导的紧密连接损伤，修复表皮屏障。临床试验显示，本维莫德可减轻和消除皮损，缓解瘙痒。而本维莫德乳膏的不良反应大多数为轻中度，包括用药部位瘙痒、红斑和毛囊炎等。针对特殊部位及人群的治疗需求，《共识》作出明确规范：在面部、颈部、皱褶部位等皮肤薄嫩区域，应避免长期应用糖皮质激素导致的皮肤萎缩风险，建议选择药物强度适中、剂型温和的外用药物。“泽立美本维莫德乳膏的双重作用机制对解决我国AD患者共存的炎症反应和屏障缺陷具有独特优势。”张建中教授在解读共识时强调，“尤其为儿童和激素禁忌人群提供了更安全的治疗路径。”《共识》的发布将指导各级医疗机构规范AD外用药物选择，推动我国特应性皮炎诊疗标准化进程。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2576837149","isCrawlerRequest":true}